Testing effectiveness (Phase 2)Study completedNCT03732352
What this trial is testing
18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients with EGFR Activated Recurrent Glioblastoma
Who this might be right for
EGFR Gene AmplificationEGFR Gene MutationGlioblastoma+3 more
Jonsson Comprehensive Cancer Center 12